ArticleFrontiers in cardiovascular medicine2026
Homocystinuria presenting with cerebral venous thrombosis: a case report highlighting progressive thrombosis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Homocystinuria is a hereditary metabolic disorder primarily caused by defects in enzymes involved in methionine metabolism, resulting in excessive accumulation of homocysteine and its metabolites in the blood and urine. Cerebral venous sinus thrombosis (CVST), premature atherosclerosis, and other thromboembolic events are among the most serious clinical manifestations of homocystinuria. Case presentation: We report a 13-year-old boy who initially presented with headache, followed by progressive disturbance of consciousness and status epilepticus. Cranial magnetic resonance imaging (MRI) revealed superior sagittal sinus thrombosis. He was transferred to a tertiary hospital, where he underwent emergency thrombus aspiration under digital subtraction angiography (DSA) guidance and received low-molecular-weight heparin (LMWH) anticoagulation. Although endovascular aspiration combined with LMWH controlled the seizures, his venous thrombosis continued to progress. He subsequently developed lower-extremity deep vein thrombosis, acute pulmonary embolism, and ventricular fibrillation. Clinical biochemical evaluation and genetic testing confirmed classic homocystinuria. Targeted therapy with warfarin, aspirin, vitamin B6, folic acid, and betaine resulted in a favorable prognosis. Conclusion: Early etiological screening, including genetic testing, should be prioritized in young patients with unexplained or recurrent thrombosis to optimize treatment and prognosis. Rational use of anticoagulants combined with targeted metabolic therapy (vitamin B6, folic acid, betaine) and antiplatelet therapy is critical for improving outcomes in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.